Tuesday, 26 September 2023, 9:40 PM
Site: EUPATI Open Classroom
Course: EUPATI Open Classroom (EUPATI Open Classroom)
Glossary: Glossary
C
Committee for Orphan Medicinal ProductsCommittee for Orphan Medicinal Products (COMP) http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000263.jsp" |
Committee for Proprietary Medicinal ProductsCommittee for Proprietary Medicinal Products (CPMP) http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000094.jsp" |
Committee for Veterinary Medicinal ProductsCommittee at the European Medicines Agency. http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000262.jsp" |
Committee on Herbal Medicinal ProductsCommittee on Herbal Medicinal Products (HMPC) http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_000264.jsp" |
Common European Submission PlatformCommon European Submission Platform (CESP) http://cesp.hma.eu" |
Common Technical DocumentThe Common Technical Document (CTD) is an internationally agreed format for the preparation of marketing applications to regulatory authorities for new medicines approval. The CTD is divided into five modules, where modules 2 to 5Â constitute the actual CTD and module 1 differs according to the region. The modules are:
|
Community Advisory BoardCommunity Advisory Board |
Compassionate useMethod of providing an unlicensed medicine prior to final approval by a regulatory (competent) authority for use in humans. This procedure is used with very sick individuals who have no other treatment options. Often, case-by-case approval must be obtained for compassionate use of a medicine or therapy. |
Competent AuthorityCompetent Authority |
Complementary DNAComplementary DNA |